AMAG Pharmaceuticals Inc

NASDAQ:AMAG   3:59:57 PM EDT
13.68
+0.01 (+0.07%)
4:05:11 PM EDT: $13.68 0.00 (0.00%)
Debt Financing / Related, Share Repurchases, Earnings Announcements

Covis Group Announces Agreement To Acquire AMAG Pharmaceuticals

Published: 10/01/2020 17:37 GMT
AMAG Pharmaceuticals Inc (AMAG) - Covis Group Announces Agreement to Acquire Amag Pharmaceuticals.
Amag Pharmaceuticals Inc - Deal for a Purchase Price of $13.75 per Share in Cash.
Amag Pharmaceuticals Inc - Deal for Approximately $647 Million.
Amag Pharmaceuticals - Covis Plans to Finance Transaction With Cash on Hand, and a Combination of Committed Debt and Equity Financing.
Amag Pharmaceuticals Inc - There is No Financing Condition to Obligations of Covis to Consummate Transaction.
Amag Pharmaceuticals Inc - As Part of Transaction, Covis Intends to Enter Into an Amended and Restated Credit Facility With Its Current Lenders.
Amag Pharmaceuticals Inc - All Board Members and Executive Officers of Amag Have Agreed to Tender Their Shares in Favor of Transaction.
Amag Pharmaceuticals Inc - Lenders Will Provide Covis Up to a $460 Million Senior Secured Incremental Term Loan and a $55 Million Secured Revolver.
Amag Pharmaceuticals - Proceeds From Covis Debt Financing, Plus Equity Commitments From Equity Sponsor, to Be Used to Pay Cash Purchase Price for Deal.
Amag Pharmaceuticals Inc - Deal for About $498 Million on a Fully Diluted Basis.
Amag Pharmaceuticals - Proceeds From Covis Debt Financing, Plus Equity Commitments From Equity Sponsor, to Be Used to Repay Any Existing Amag Debt.
Amag Pharmaceuticals Inc - Covis Debt Financing Amount Will Be Added to Covis' Current $450 Million Term Loan Facility With Lenders.
Revenue is expected to be $60.56 Million
Adjusted EPS is expected to be -$0.01

Next Quarter Revenue Guidance is expected to be $64.16 Million
Next Quarter EPS Guidance is expected to be $0.05

More details on our Analysts Page.